Fat Burners

Twincret (Tirzepatide) 20 mg SunSci Pharmaceuticals

SunSci Pharmaceuticals

345,00

In Stock (100 available)

Twincret (Tirzepatide) 20 mg SunSci Pharmaceuticals (20 mg) — Precision-dosed by SunSci Pharmaceuticals for consistent results, tirzepatide is a dual GIP/GLP-1 receptor agonist representing th…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

Twincret (Tirzepatide) 20 mg SunSci Pharmaceuticals — tirzepatide from SunSci Pharmaceuticals at 20 mg. Dual GIP and GLP-1 receptor agonist. Produces larger weight-loss effect than pure GLP-1 agonists in clinical trials.

Key Benefits

  • Dual GIP + GLP-1 receptor agonist — broader incretin action than semaglutide
  • Clinical data: 15–21% body-weight reduction at therapeutic dose over 72 weeks
  • Superior HbA1c reduction vs semaglutide in head-to-head trials
  • Weekly SubQ dosing with graduated titration
  • Currently the most effective commercial weight-loss pharmacotherapy
  • Each unit dosed at 20 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Clinical dosing titration (Mounjaro/Zepbound protocol): weeks 1–4: 2.5 mg/week; weeks 5–8: 5 mg/week; weeks 9–12: 7.5 mg/week; weeks 13–16: 10 mg/week; week 17–20: 12.5 mg/week; week 21+: 15 mg/week maintenance. Slow titration is standard — faster escalation amplifies GI side-effects.

How It Works

First-in-class dual-agonist: activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The dual-mechanism produces additive effects on insulin secretion, appetite suppression, and adipose-tissue metabolism that single-target GLP-1 agonists don’t match.

Pharmacokinetics

Plasma half-life approximately 5 days. Weekly SubQ dosing (abdomen/thigh/upper arm). Steady-state at 4 weeks. Reconstituted vial stable in fridge for 21 days after first use.

Potential Side Effects

GI side-effects similar to semaglutide (nausea, vomiting, diarrhoea, constipation) but frequency slightly higher due to dual mechanism. Dose-dependent muscle-mass loss requires concurrent resistance training. Pancreatitis rare. Gallbladder events possible at high maintenance dose.

Cycle & Stacking Guide

16–24+ week protocols. Titrate slowly. Resistance training + high-protein diet non-negotiable to preserve lean mass. Post-discontinuation weight rebound documented; long-term maintenance strategy required (gradual taper or weekly micro-dose).

Manufacturer Notes

SunSci Pharmaceuticals produces semaglutide pens and growth hormone products. Cold-chain shipping for all biological products.

Storage & Handling

Lyophilised (freeze-dried) form: stable at 2–8 °C in the sealed vial for the duration printed on the label. After reconstitution with bacteriostatic water, store reconstituted solution at 2–8 °C and use within 30 days. Do not freeze reconstituted peptide — ice crystals denature the molecule. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Twincret (Tirzepatide) 20 mg SunSci Pharmaceuticals”

Your email address will not be published. Required fields are marked *

Tirzepatide

Physical & Chemical Properties for Research Purposes
Chemical structure of Tirzepatide (C225H348N48O68) for laboratory analysis
2D structural representation · PubChem CID 156588324 ↗
Chemical Identity
# CAS Registry Number 2023788-19-2
Σ IUPAC Name Dual GIP/GLP-1 receptor agonist, 39-amino acid synthetic peptide with C20 diacid fatty acid side chain
F Molecular Formula C225H348N48O68
M Molecular Weight 4813.53 g/mol
Melting Point N/A (peptide, lyophilized) °C
Solubility Soluble in water upon reconstitution
Biological Half-life 5 days (SC)
PubChem CID 156588324 ↗
Pharmacological Profile
Aromatization None
Hepatotoxicity None
Known trade names: Mounjaro, Zepbound, Tirzepatide

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.